Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 50.01 · gapped above the open, then crossed back over prior close. High/low 51.99 at 8:15 am ET, 46.72 at 1:15 pm ET.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
6 readings, 3 filed under bull and 3 under bear. Every figure is ours; the model chose the side.
the bull case· 3
7
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
of the funds on file reporting a position in SRRK
n-portas of Jun 30 '26+0.91%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized8 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '261.16%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 12 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
309 managers report a position worth $7.7B between them, and 28 of them hold 80% of it.
tall tick = annual report · 1 on record
Of the 6 companies Scholar Rock Holding Corp moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
SRRK (Scholar Rock Holding Corp) has 5 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: OWL +0.39%, in financials.